MENU
+Compare
BCAX
Stock ticker: NASDAQ
AS OF
Oct 17 closing price
Price
$18.25
Change
-$0.43 (-2.30%)
Capitalization
996.68M

BCAX Bicara Therapeutics Inc. Forecast, Technical & Fundamental Analysis

Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors... Show more

BCAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for BCAX with price predictions
Oct 16, 2025

BCAX's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for BCAX turned positive on September 29, 2025. Looking at past instances where BCAX's MACD turned positive, the stock continued to rise in of 8 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 26, 2025. You may want to consider a long position or call options on BCAX as a result. In of 17 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

BCAX moved above its 50-day moving average on September 26, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for BCAX crossed bullishly above the 50-day moving average on September 30, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 3 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BCAX advanced for three days, in of 59 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 15 cases where BCAX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 8 cases where BCAX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

BCAX broke above its upper Bollinger Band on September 29, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.290) is normal, around the industry mean (24.427). P/E Ratio (0.000) is within average values for comparable stocks, (54.848). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.179). Dividend Yield (0.000) settles around the average of (0.037) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (351.995).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly better than average price growth. BCAX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BCAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
BCAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SAMKX40.590.19
+0.47%
SA US Core Market
MLPEX7.110.03
+0.42%
Invesco SteelPath MLP Select 40 C
FSSKX89.88N/A
N/A
Fidelity Stock Selec-Class K
THCGX31.75-0.04
-0.13%
Thornburg Small/Mid Cap Growth A
EEOFX16.52-0.22
-1.31%
Pear Tree Essex Environmental Opps Odnry

BCAX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, BCAX has been loosely correlated with SYRE. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if BCAX jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCAX
1D Price
Change %
BCAX100%
-0.69%
SYRE - BCAX
42%
Loosely correlated
+0.23%
IMNM - BCAX
41%
Loosely correlated
+0.86%
VTYX - BCAX
41%
Loosely correlated
+1.01%
XENE - BCAX
39%
Loosely correlated
+0.64%
ORKA - BCAX
39%
Loosely correlated
-4.84%
More